EMD Millipore Opens New R&D Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMD Millipore Opens New R&D Center
The facility, which includes state-of-the-art formulation, analytical and synthetic laboratories as well as a customer training center, will focus on bioavailability enhancement and oral dosage formulations.


EMD Millipore announced that it has opened a new R&D center for formulation in Darmstadt, Germany, which combines state-of-the-art formulation, analytical and synthetic laboratories and a customer training center in a single facility.

With EMD Millipore’s expertise in developing oral dosage formulations and drug delivery systems, the center will focus on addressing bioavailability and formulation challenges by using the company’s portfolio of innovative technologies and products. It will provide hands-on support to assist customers in their drug development.

EMD Millipore’s core areas are inorganic carriers, solid dispersion formulation techniques and excipients for controlled release, with technologies in granulation, tableting, film coating, direct compression and freeze drying.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here